The U.S. Food and Drug Administration approved Vanda Pharmaceuticals’ oral drug Nereus (tradipitant) for preventing vomiting due to motion sickness, based on three pivotal studies including two phase III trials conducted in real-world boat conditions. The approval ends a decades-long gap in new pharma options for motion sickness and positions Vanda to launch the product in early 2026. Market reaction was immediate: Vanda’s shares jumped sharply on the news, reflecting investor optimism about near-term commercial uptake and a contained regulatory path.